Grayanotoxin I (GTX I) binds to receptor site 2 on voltage-gated sodium channels (VGSCs), the same binding site targeted by other lipophilic toxins, including veratridine, batrachotoxin, and aconitine. This site, located within the channel’s transmembrane domain, is distinct from the neurotoxin site 1 targeted by tetrodotoxin and saxitoxin, which block channel opening rather than preventing inactivation. The site 2 toxin class shares a common pharmacological outcome: they prevent the fast inactivation gate of the sodium channel from closing after depolarisation-triggered opening.
Under normal physiology, a VGSC opens in response to membrane depolarisation, allows a brief rush of sodium ions into the cell, and then spontaneously inactivates within milliseconds. The inactivation gate (the h-gate) closes, terminating sodium entry. This brief, self-terminating sodium current is the fundamental event of action potential generation. GTX I binding at receptor site 2 stabilizes the channel in its open or inactivated-but-open conformation, preventing the conformational change that closes the inactivation gate. The result is a prolonged, non-terminating sodium current that maintains the cell in a depolarised state far beyond the normal action potential duration.
Key Takeaways
- GTX I binds receptor site 2 on voltage-gated sodium channels and prevents fast inactivation gate closure, producing prolonged sodium influx and sustained cell depolarisation.
- Multiple Nav subtypes are affected, with the cardiac Nav1.5 isoform showing high sensitivity, consistent with the predominance of cardiac effects in the clinical presentation.
- A lipophilic mechanism facilitates membrane partitioning and access to the site 2 binding pocket, contributing to relatively rapid toxin onset after ingestion.
- GTX I also activates vagal afferent fibers, producing reflex parasympathetic overdrive that amplifies the direct cardiac effect. This vagal component explains atropine’s clinical effectiveness.
- Direct structural antagonism at site 2 by atropine does not occur; its clinical efficacy operates through blockade of downstream muscarinic consequences of vagal activation.
Nav Subtype Selectivity
Voltage-gated sodium channels exist as multiple subtypes (Nav1.1 through Nav1.9) with tissue-specific expression patterns. Nav1.5 is the primary cardiac isoform; Nav1.4 predominates in skeletal muscle; Nav1.1, Nav1.2, Nav1.3, and Nav1.6 are central nervous system isoforms; Nav1.7, Nav1.8, and Nav1.9 are peripheral sensory neuron isoforms. The site 2 toxin class, including GTX I, shows varying affinity across these subtypes.
Electrophysiological studies using expressed Nav subtypes in heterologous systems (Xenopus oocytes and HEK293 cells) have documented GTX I activity across multiple subtypes, with the cardiac Nav1.5 channel showing high sensitivity, a finding consistent with the predominance of cardiac effects in the clinical toxidrome. Nav1.4 (skeletal muscle) and Nav1.7 (peripheral sensory) also show GTX I sensitivity, consistent with the muscle weakness and paraesthesia reported in clinical cases. The relative contribution of each subtype to the overall clinical picture has not been precisely deconvoluted in human cases.
Structural Binding Determinants
Mutagenesis studies have identified specific amino acid residues within the Nav channel transmembrane domains that are critical for site 2 toxin binding. Key determinants include residues in transmembrane segments IIS4-S5 and IIIS4-S5 of the channel protein. The lipophilic character of GTX I facilitates membrane partitioning, which is thought to be the first step in reaching the site 2 binding pocket, a mechanism shared with other lipophilic site 2 toxins and relevant to understanding the relatively rapid onset of toxicity after ingestion compared to toxins that act at extracellular sites.
The structural similarity between GTX I and other site 2 toxins (veratridine, batrachotoxin) at their respective pharmacophoric regions, despite substantial overall structural differences, supports a shared interaction with a conserved receptor site geometry. This structural pharmacology provides the theoretical basis for understanding cross-sensitivity and for predicting pharmacological antagonism. Atropine’s efficacy in clinical management reflects its blockade of the downstream parasympathetic consequences of sodium channel overstimulation rather than direct antagonism at the site 2 binding pocket itself.
Vagal Activation and Autonomic Effects
The bradycardia and hypotension of grayanotoxin poisoning are not solely a direct consequence of Nav1.5 modulation in cardiac myocytes. GTX I also activates sodium channels in vagal afferent nerve fibers, sensory neurons that carry signals from the heart, lungs, and gastrointestinal tract to the brainstem. This vagal afferent activation triggers a reflex increase in parasympathetic outflow to the heart via the vagus nerve, producing additional suppression of sinoatrial automaticity and AV conduction on top of any direct cardiac myocyte effect.
The clinical implication of this dual mechanism, direct cardiac Nav1.5 modulation plus reflexive vagal activation, is that the bradycardia of grayanotoxin poisoning has a significant cholinergic (vagal) component, which is why it is highly responsive to atropine. If the bradycardia were purely a direct Nav1.5 effect, atropine might be expected to be less effective, as it acts on muscarinic receptors rather than sodium channels.
